
News|Articles|September 1, 2003
Treatment for male pattern baldness delays prostate cancer
Finasteride (Propecia, Merck), an inhibitor of 5a-reductase, prevents or delays the appearance of prostate cancer by 24.8% (P<.001), according to researchers from the University of Texas Health Science Center, San Antonio, Texas.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Biosimilars in 2025: A year of firsts
2
What IRA drug prices will mean for PBMs, health plans and patients
3
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
4
FDA approves first postmenopausal libido treatment, Addyi
5






















































